A review of agents in late-stage development for the treatment of Parkinson disease (March 2006).
FDA Sets Review Date for Linvoseltamab for Multiple Myeloma
The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma is July 10, 2025.
Read More
FDA Approves Combination Antibiotic for Complicated Infections
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
FDA Sets Review Date for Chronic Lung Disease Therapy
Regulators have set a goal of Aug. 12, 2025, for brensocatib to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung disease.
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a refillable ocular implant.
FDA Approves Third Biosimilar of Actemra
The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.
Evernorth Drives Cigna's Strong Revenue Growth and Focuses on Biosimilars and Drug Affordability